Multicenter study reveals worse survival outcomes in early-stage oral tongue cancer associated with SARIFA, suggesting its potential as a treatment guide.
Stroma AReactive Invasion Front Areas (SARIFA) has recently been introduced as a prognostic indicator. The prognostic value of SARIFA has not been studied in early-stage oral tongue squamous cell carcinoma (OTSCC). A total of 287 cases of early-stage OTSCC were included in this multicenter study. SARIFA was defined as direct contact between tumor cells and the adipose tissue, and was assessed in hematoxylin and eosin (HE)-stained sections. In early-stage OTSCC, SARIFA-positive tumors were associated with worse disease-specific survival with a hazard ratio (HR) of 1.86 (95% CI 1.06–3.28, P = 0.032), overall survival (HR 1.52, 95% CI 1.06–2.19, P = 0.023) and disease-free survival (HR 1.79, 95% CI 1.09–2.93, P = 0.021). SARIFA is a histomorphology-based prognosticator, that can identify cases with early-stage OTSCC who might benefit from a multimodality treatment protocol.
No takes yet. Share an insight, caveat, or question.
Almangush et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: